WTZ Cancer Center Director Univ. Prof. Dr. med. Angelika Eggert ...

WTZ Cancer Center Director 

Univ. Prof. Dr. med. Angelika Eggert 

Ten most important publications: 

Schramm A, Vandesompele J, Schulte JH, Dreesmann S, Kaderali L, Brors B, Eils R, Speleman F, 

Eggert A. Translating expression profiling into a clinically feasible test to predict neuroblastoma 

outcome. 

Clinical Cancer Res. 2007, 13:1459-65. IF 6.1 

Steinbach D, Schramm A, Eggert A, Onda M, Dawczynski K, Rump A, Pastan I, Wittig S, 

Pfaffendorf N, Voigt A, Zintl F, Gruhn B. Identification of a set of seven genes for the monitoring 

of minimal residual disease in pediatric acute myeloid leukemia. 

Clin Cancer Res. 2006;12:2434-4. IF 6.1 

Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, 

Warnat P, Brors B, Eils J, Eils R, Eggert A. Prediction of clinical outcome and biological 

characterization of neuroblastoma by expression profiling. 

Oncogene 2005, 24:7902-7912. IF 6.8 

Schulte JH, Schramm A, Klein-Hitpass L, Klenk M, Wessels H, Schweigerer L, Brodeur, G.M., 

Havers W, Eggert A. 

Microarray analysis reveals differential gene expression patterns and regulation of single target 

genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. 

Oncogene 2005, 24:165-177.IF 6.8 

Sitek B, Apostolov O, Stuhler K, Pfeiffer K, Meyer HE, Eggert A, Schramm A. Identification of 

dynamic proteome changes upon ligand-activation of Trk-receptors using two-dimensional 

fluorescence difference gel electrophoresis and mass spectrometry. 

Mol Cell Proteomics 2005, 18. IF 9.6 

Grasemann C, Gratias S, Stephan H, Schüler A, Schramm A, Klein-Hitpass L, Rieder H, 

Schneider S, Kappes F, Eggert A, Lohmann D. Gains and overexpression identify DEK and 

E2F3 as targets of chromosome 6p gains in retinoblastoma. 

Oncogene 2005, 24:6441-6449. IF 6.8 

Eggert A, Grotzer MA, Ikegaki N, Liu X, Kisselbach KD, Evans AE, Brodeur GM. Expression of 

the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators 

in SH-SY5Y neuroblastoma cells. 

Cancer Research 2002, 62: 1802-1808. IF 8.4 

Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM. 

Resistance to chemotherapy mediated by TrkB in neuroblastomas. 

Cancer Research 2002, 62:6462-6466. IF 8.4 

Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ikegaki N, Brodeur GM. Resistance to tumor 

necrosis factor-related apoptosis-inducing ligand-induced apoptosis in neuroblastoma cells 

correlates with a loss of caspase-8 expression. 

Cancer Research 2001, 61: 1314-1319. IF 8.4 

Eggert A, Grotzer MA, Ikegaki N, Zhao H, Cnaan A, Brodeur GM, Evans AE. Expression of 

neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms’ Tumor. 

J. Clinical Oncology 2001,19: 689-696. IF 13.6

Associate Director Medical Oncology 

Univ.-Prof. Dr. med. Martin Schuler 

Ten most important publications (ISI-IF 2006): 

C.A. Marques, P.S. Hähnel, C. Wölfel, S. Thaler, Ch. Huber, M. Theobald, and M. Schuler: An 

immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated 

tumor suppression. 

Blood 111:1413-1419 (2008) IF 10.4 

S. Hoffarth, A. Zitzer, R. Wiewrodt, P.S. Hähnel, V. Beyer, A. Kreft, S. Biesterfeld, and M. Schuler: 

pp32/PHAPI determines the apoptosis response of non-small-cell lung cancer. 

Cell Death Differ. 15:161-170 (2008) IF 7.5 

C. Huber, N. Bobek, J. Kuball, S. Thaler, S. Hoffarth, Ch. Huber, M. Theobald, and M. Schuler: 

Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted 

cytotoxic T lymphocytes in vitro and in vivo. 

Cell Death Differ. 12:317-325 (2005) IF 7.5 

J.E. Chipuk, T. Kuwana, L. Bouchier-Hayes, N.M. Droin, D.D. Newmeyer, M. Schuler, and 

D.R. Green: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization 

and apoptosis. 

Science 303:1010-1014 (2004) IF 30.0 

C.L. Scott, M. Schuler, V.S. Marsden, A. Egle, M. Pellegrini, D. Nesic, S. Gerondakis, S.L. Nutt, 

D.R. Green, and A. Strasser: Apaf-1 and Caspase-9 do not act as tumor suppressors in 

myc-induced lymphoma genesis or mouse embryo fibroblast transformation. 

J. Cell Biol. 164:89-96 (2004) IF 10.2 

J.E. Chipuk, U. Maurer, D.R. Green, and M. Schuler: Pharmacologic activation of p53 elicits 

Bax-dependent apoptosis in the absence of transcription. 

Cancer Cell 4:371-381 (2003) IF 24.1 

J. Milosevic, S. Hoffarth, C. Huber, and M. Schuler: The DNA damage-induced decrease of 

Bcl-2 is secondary to the activation of apoptotic effector caspases. 

Oncogene 22:6852-6856 (2003) IF 6.6 

J. Kuball, S.F. Wen, D. Atkins, J. Leissner, P. Meinhardt, E. Quijano, H. Engler, B. Hutchins, 

D.C. Maneval, M.J. Grace, M.A. Fritz, S. Störkel, J.W. Thüroff, Ch. Huber, and M. Schuler: 

Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by 

intravesical vector instillation. 

J. Clin. Oncol. 20:957-965 (2002) IF 13.6 

M. Schuler, R. Herrmann, J.L.P. De Greve, A.K. Stewart, U. Gatzemeier, D.J. Stewart, L. Laufman, 

R. Gralla, J. Kuball, R. Buhl, C.P. Heussel, F. Kommoss, A.P. Perruchoud, F.A. Shepherd, 

M.A. Fritz, J.A. Horowitz, Ch. Huber, and C. Rochlitz: Adenovirus-mediated wild type p53 gene 

transfer in patients receiving chemotherapy for advanced non-small cell lung cancer: Results of 

a multicenter phase II study. 

J. Clin. Oncol. 19:1750-1758 (2001) IF 13.6 

M. Schuler, E. Bossy-Wetzel, J.C. Goldstein, P. Fitzgerald, and D.R. Green: p53 induces apoptosis 

by caspase activation through mitochondrial cytochrome c release. 

J. Biol. Chem. 275:7337-7342 (2000) IF 5.8

Associate Director Radiation Oncology 

Univ. Prof. Dr. med. Martin Stuschke 


Pottgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, 

Gauler T, Antoch G, Bockisch A, Stuschke M. Value of 18F-fluoro-2-deoxy-D-glucose-positron 

emission tomography/computed tomography in non-small-cell lung cancer for prediction of 

pathologic response and times to relapse after neoadjuvant chemoradiotherapy. 

Clin Cancer Res. 2006;12:97-106 IF 5.6 

Sak A, Stuschke M, Wurm R, Schroeder G, Sinn B, Wolf G, Budach V. Selective inactivation of 

DNAdependent protein kinase with antisense oligodeoxynucleotides: consequences for the 

rejoining of radiation-induced DNA double-strand breaks and radiosensitivity of human cancer 

cell lines. 

Cancer Res 2002; 62: 6621-4. IF 8.4 

Stuschke M, Sak A, Wurm R, Sinn B, Wolf G, Stuben G, Budach V. Radiation-induced apoptosis 

in human non-small-cell lung cancer cell lines is secondary to cell-cycle progression beyond the 

G2-phase checkpoint. 

Int J Radiat Biol 2002; 78: 807-19. IF 2.1 

Sak A, Stueben G, Groneberg M, Bocker W, Stuschke M. Targeting of Rad51-dependent 

homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. 

Br J Cancer. 2005; 28:1089-97. IF 3.7 

Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, 

Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery 

in patients with locally advanced squamous cell carcinoma of the esophagus. 

J Clin Oncol. 2005;23:2310-7. IF 9.8 

Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke 

K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD. Hyperfractionated 

accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than doseescalated 

hyperfractionated accelerated radiation therapy alone in locally advanced head and 

neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer 

Society 95-06 Prospective Randomized Trial. 

J Clin Oncol. 2005;23:1125-35. IF 9.8 

Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stuschke M, Thews O, Vaupel P. Erythropoietin 

restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude 

mice. 

Int J Radiat Oncol Biol Phys. 2003; 55:1358-62. IF 4.3 

Marnitz S, Stuschke M, Bohsung J, Moys A, Reng I, Wurm R, Budach V. Intraindividual 

comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy 

in the therapy of locally advanced non-small cell lung cancer a planning study. 

Strahlenther Onkol 2002;178: 651-8. IF 3.1 

Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S. Update 

on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental 

predispositions, clinical manifestations, and therapy. 

Lancet Infect Dis 2002; 2: 281-92. IF 10.8 

Pottgen C, Eberhardt W, Bildat S, Stuben G, Stamatis G, Hillejan L, Sohrab S, Teschler H, 

Seeber S, Sack H, Stuschke M. Induction chemotherapy followed by concurrent chemotherapy 

and definitive high dose radiotherapy for patients with locally advanced non-small-cell lung 

cancer (stages IIIa/IIIb): a pilot phase I/II trial. 

Ann Oncol 2002; 13: 403-11. IF 4.3

Associate Directors Surgical Oncology 

Prof. Dr. med. Andreas Paul, MSc, FRCS 


Paul A, Marelli D, Wilson JAS, Chiu RC-J, Mulder DS: Does the Surgical Trauma of 

„Exploratory Thoraco-tomy“ Affect Survival of Patients with Bronchogenic Carcinoma? 

Can J Surg, Vol. 32, 322-326 (1989) 

Paul A, Troidl H, Williams JI, Rixen D, Langen R and The Cologne Hernia Study Group: 

Randomized trial of modified Bassini versus Shouldice inguinal hernia repair. 

Brit J Surg, Vol. 81, 1531-1534 (1994) 

Lang H, Sotiropoulos GC, Dömland M, Frühauf NR, Paul A, Husing J, Malagó M, Broelsch CE: 

Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. 

Brit J Surg, 92: 198 – 202 (2005) 

Sotiropoulos GC, Paul A, Molmenti E, Lang H, Frilling A, Napieralski BP, Nadalin S, Treckmann J, 

Brokalaki EI, Gerling T, Broelsch CE, Malagó M: Liver Transplantation for Hepatocellular 

Carcinoma in Cirrhosis within the Eurotransplant Area: An Additional Option with “Livers that 

Nobody Wants” 

Transpl, 80: 897 – 902 (2005) 

Ruh J, Lang H, Paul A, Dirsch O, Broelsch CE: Surgical Aspects in the Therapy of Primary 

Sarcoma of the Vena Cava. 

J Am Coll Surg, 202(3): 559-62 (2006) 

Sotiropoulos GC, Lang H, Frilling A, Molmenti EP, Paul A, Nadalin S, Radtke A, Brokalaki EI, 

Saner F, Hilgard P, Gerken G, Broelsch CE, Malagó M : Resectability of Hepatocellular Carcinoma: 

Evaluation of 333 Consecutive Cases at a Single Hepatobiliary Specialty Center and Systematic 

Review of the Literature. 

Hepatogastroenterology, 53(69): 322-9 (2006) 

Frilling A, Malago M, Weber F, Paul A, Nadalin S, Sotiropoulos GC, Cicinnati V, Beckebaum S, 

Bockisch A, Mueller- Brand J, Hofmann M, Schmid KW, Gerken G, Broelsch CE: Liver 

Transplantation for Patients With Metastatic Endocrine Tumors: Single-Center Experience With 

15 Patients. 

Liver Transpl, 12(7): 1089-96 (2006) 

Paul A, Treckmann J, Gallinat A, Witzke O, Vester U, Broelsch CE: Current concepts in Transplant 

Surgery: Laparoscopic Living Donor of the Kidney. 

Langenbecks Arch Surg Sep;392:501-509 (2007) 

Treckmann J, Nagelschmidt M, Saad S, Hoffmann J, Waldmann KH, Broelsch CE, Paul A: 

Decreasing surgical complications in porcine kidney autotransplantation by a new technique of 

implantation. 

Journal of Experimental Animal Science, 43: 231 – 236 (2007) 

Treckmann J, Minor T, Saad S, Özcelik A, Malago M, Broelsch CE, Paul A: Retrograde Oxygen 

Persufflation Preservation of Human Livers: A Pilot Study. 

Liver Transpl, 14(3): 358-64 (2008)

Priv.-Doz. Dr. med. Georg Taeger 

Klinik für Unfallchirurgie 


Taeger G, Podleska L.E, Schmidt B, Ziegler M, Nast-Kolb D. Comparison of Diamond-Like-Carbon 

and Alumina-Oxide articulating with Polyethylene in Total Hip Arthroplasty. 

Mat Sci Tech Eng 2003;34(12):1094-1100 

Wimmer MA, Sprecher C, Hauert R, Taeger G, Fischer A. Tribochemical reactions on 

metal-on-metal hip joint bearings – in vitro results. 

Wear 2003;255:1007-1014 

Ruchholtz S, Waydhas C, Lewan U, Pehle B, Taeger G, Kuehne C, Nast-Kolb D. Free abdominal 

fluid on ultrasound in unstable pelvic ring fracture: Is laparotomy always necessary? 

J Trauma 2004;57(8):278-286 

Waydhas C, Taeger G, Zettl R, Oberbeck R, Nast-Kolb D. Improved student preparation from 

implementing active learning sessions and a standardized curriculum in the surgical examination 

course Medical Teacher 2004;26(7):621-624 

Taeger G, Ruchholtz S, Niebel W, Müller S, Nast-Kolb D. Isolated limb perfusion with TNF-α and 

Melphalan in nonresectable soft tissue sarcomas Unfallchirurg 2004; 107(7):619-624* 

Büscher R, Taeger G, Dudzinski W, Gleising B, Wimmer MA, Fischer A. Subsurface 

microstructure of metal-on-metal hip joints and ist relationship to wear particle generation 

J Biomed Mater Res 2005;72B:206-214 

Taeger G, Ruchholtz S, Waydhas Ch, Lewan U, Schmidt B, Nast-Kolb D. Damage 

Control Orthopedics in Patients with Multiple Injuries is Effective, Time Saving and 

Safe J Trauma 2005;59:409-416 

Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G, Niebel W, Erhard J, Ebeling P, 

Zeth M, Taeger G, Seeber S, Flasshove M, Schutte J. Resection of residual disease in patients 

with metastatic gastrointestinal stromal tumors responding to treatment with imatinib 

Int J Cancer 2005;117(2):316-325 * 

Podleska L.E, Weuster M, Dose E, Kühne C.A, Nast-Kolb D, Ruchholtz S, Taeger G. The impact of 

nanocolloidal wear particles on human mononuclear cells Mat Sci Eng Tech 2006;37(6):563-569 

Taeger G, Grabellus F, Podleska LE, Müller S, Ruchholtz S. Effectiveness of regional 

chemotherapy with TNF- α/Melphalan in advanced soft tissue sarcoma of the extremities 

Int J Hyperthermia 2008; pub.onlineDOI: 10.1080/02656730701868387*

Associate Director Regional Affairs 

Dr. med. Wilfried Eberhardt 

Klinik für Innere Medizin/Tumorforschung 

Ten most important publications 

Pöttgen C, Eberhardt W, Bildat S, Stüben G, Stamatis G, Hillejan L, Sohrab S, Teschler H, 


and definitive high-dose radiotherapy for patients with locally advanced non-small cell lung cancer 

(stage IIIa/IIIb): a pilot phase I/II trial. 

Ann Oncol 13: 403-411 (2002) IF 4.3 

Eberhardt WE, Albain KS, Pass H, Putnam JB, Gregor A, Assamura H, Mornex F, Senan S, 

Belderbos J, Westeel V, Thomas M, Van Schil P, Vansteenkiste J, Manegold C, Mirimanoff RO, 

Stuschke M, Pignon J, Rocmans P, Shepherd FA. Induction treatment before surgery for 

non-small cell lung cancer. 

Lung Cancer. 2003 Dec;42 Suppl 1:S9-14. IF2.9 

International Adjuvant Lung Cancer Trial Collaborative Group (W.Eberhardt – active Group 

member). Cisplatin-based adjuvant chemotherapy in patients with completely resected 

non-small-cell lung cancer. 

N Engl J Med 2004; 2004; 350:351-60 IF 38.6 

Eberhardt W, Gauler T, Hepp R, Korfee S, Pottgen C, Stamatis G, Stuschke M. The role of 

chemoradiotherapy in the treatment of stage III non-small-cell lung cancer. 

Ann Oncol. 2004;15 Suppl 4:iv71-80. IF 4.3 

Scagliotti GV, Smit E, Bosquee L, O'Brien M, Ardizzoni A, Zatloukal P, Eberhardt W, Smid- 

Geirnaerdt M, de Bruin HG, Dussenne S, Legrand C, Giaccone G; European Organisation for 

Research and Treatment of Cancer (EORTC) Lung Cancer Group (LCG). A phase II study of 

paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). 

Lung Cancer. 2005 Oct;50(1):91-6. IF 3.2 

Pöttgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, 




Clin Cancer Res. 2006 Jan 1;12(1):97-106. IF 5.6 

Marra A, Eberhardt WE, Pöttgen C, Theegarten D, Korfee S, Gauler T, Stuschke M and G. 

Stamatis. Induction chemotherapy, concurrent chemoradiation, and surgery for Pancoast tumor. 

Mature results of a feasibility trial. Accepted for publication in: 

Eur Resp Journal 2006 IF 3.1 

Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, 

Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; 

IALT Bio Investigators (W.Eberhardt, Theegarten – active Group members). DNA repair by 

ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. 

N Engl J Med. 2006 Sep 7;355(10):983-91. IF 38.6 

Pöttgen C, Eberhardt W, Grannass A, Korfee S, Stüben G, Teschler H, Stamatis G, Wagner H, 

Passlick B, Petersen V, Budach V, Wilhelm H, Wanke I, Hirche H, Wilke HJ, Stuschke M. 

Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with 

neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. 

J Clin Oncol. 2007 Nov 1;25(31):4987-92. IF 13.2 

Motzer, Robert J., Hutson, Thomas E., et al. (W. Eberhardt study investigator). Sunitinib versus 

Interferon Alfa in Metastatic Renal-Cell Carcinoma.N Engl J Med 2007 356: 115-124 IF 38.6

2. Coordinator 

Kurt Werner Schmid, MD, MRCPath, 

Professor of Pathology, Director, 

Institute of Pathology and Neuropathology 

6. Selected publications 2005 – 2008 

Lehnerdt GF, Franz P, Zaqoul A, Schmitz KJ, Grehl S, Lang S, Schmid KW Siffert W, Jahnke K, 

Frey UH. Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell 

carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene. 

Clin Cancer Res. 2008; 14: 1753-1758. IF 6.2 

Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos, GC, Malago M, Steveling K, Reis H, 

Cicinnati VR, Schmid KW, Baba HA. Activation of the ERK and AKT signalling pathway predicts 

poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated 

with hepatitis C virus infection 

J Hepatol. 2008; 48: 83-90. IF 6.1 

Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, Siffert W, Kimmig R. The 

AA Genotype of the Regulatory BCL2 Promoter Polymorphism (938>A) Is Associated with a 

Favorable Outcome in Lymph Node Negative Invasive Breast Cancer Patients. 

Clin Cancer Res. 2007; 13:5790-7. IF 6.2 

Grabellus F, Ebeling P, Worm K, Sheu SY, Antoch G, Frilling A, Schmid KW. Double resistance 

to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal 

stromal tumour. 

Gut. 2007; 56:1025-6. IF 9.0 

Schmitz KJ, Lang H, Frey UH, Sotiropulos GC, Wohlschlaeger J, Reis H, Takeda A, Siffert W, 

Schmid KW, Baba HA. The GNAS1 T393C polymorphism is associated with the clinical course 

In patients with intrahepatic cholangiocarcinoma. 

Neoplasia 2007; 9:159-65. IF 4.9 

Sheu S-Y, Handke S, Bröcker-Preuss M, Görges R, Frey UH, Ensinger C, Öfner D, Farid NR, 

Siffert W, Schmid KW. The C allele of the GNB3 C825T polymorphism of the G protein β3- 

subunit is associated with an increased risk for the development of oncocytic thyroid tumours. 

J Pathol. 2007; 211:60-66. IF 5.8 

Frey UH, Lümmen G, Jäger T, Jöckel K-H, Schmid KW, Rübben H, Siffert W, Eisenhardt A. 

The GNAS1 T393C polymorphism predicts the clinical outcome in patients with clear cell renal 

cell carcinoma. 

Clin Cancer Res. 2006; 12:759-63 IF 5.6 

Sheu S-Y, Görges R, Ensinger C, Öfner D, Farid NR, Siffert W, Schmid KW. Different genotype 

distribution of the GNB3 C825T polymorphism of the G protein ß3 subunit in adenomas and 

differentiated thyroid carcinomas of follicular cell origin. 

J Pathol 2005; 207:430-435 IF 5.3 

Gashaw I, Grummer R, Klein-Hitpass L, Dushaj O, Bergmann M, Brehm R, Grobholz R, 

Kliesch S, Neuvians TP, Schmid KW, Ostau CV, Winterhager E. Gene signatures of testicular 

seminoma with emphasis on expression of ets variant gene 4. 

Cell Mol Life Sci. 2005; 62:2359-68. IF 4.8 

Frey UH, Alakus H, Wohlschlaeger J, Schmitz KJ, Winde G, van Calker HG, Jaeckel KH, Siffert 

W, Schmid KW. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal 

cancer. 

Clin Cancer Res. 2005; 15:5071-7. IF 5.6


Prof. Dr. Karl-Heinz Jöckel 

Director, Institute of Medical Informatics, Biometry 

and Epidemiology 

6. Selected publications 2002 – 2008: 

Wittig A, Malago M, Collette L, Huiskamp R, Buhrmann S, Nievaart V, Kaiser GM, Jöckel KH, 

Schmid KW, Ortmann U, Sauerwein WA (2008): Uptake of two 10B-compounds in liver 

metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron 

capture therapy (EORTC Trial 11001). 

Int J Cancer 122 (5): 1164-1171 IF 4.7 

Richardson, D.B., Terschuren, C., Pohlabenln, H., Jöckel K.-H., Hoffmann, W. (2007). Temporal 

patterns of association between cigarette smoking and leukemia risk. 

Cancer Causes and Control. IF 3.2 

Stang, A., Ahrens, W., Baumgardt-Elms, C., Stegmeier, C.H., Merznich, H., deVrese, M., 

Schrezenmeier, J., Jöckel K.-H (2006). Adolescent milk fat and galactose consumption and 

testicular germ cell cancer. 

Cancer Epidemiol Biomarkers Prev 15 (11): 2189-2195. IF 4.5 

Frey, U.H., Eisenhardt, A., Lümmen, G., Rübben, H., Jöckel, K.-H., Schmid, K.W., Siffert, W. 

(2005). The T393C polymorphism of the Gs gene (GNAS1) is a novel prognostic marker in 

bladder banker. 

Cancer Epidemiol Biomarkers Prev 14(4): 871-877. IF 4.5 

Stang, A., Parkin, D. M., Ferlay, J., Jöckel, K.-H. (2005). International uveal melanoma incidence 

trends in view of a decreasing proportion of morphological verification, 

Int. J. Cancer 114: 114- 123. IF 4.4 

Neuhäuser, M., Boes, T., Jöckel, K.-H. (2005). Two-part permutation tests for DNA methylation 

and microarray data. 

BMC Bioinformatics 6: 35. IF 5.4 

Neuhäuser, M., Senske, R. (2004): The Baumgartner-Weiß-Schindler test for the detection of 

differentially expressed genes in replicated microarray experiments. 

Bioinformatics 20, 3553- 3564. IF 6.0 

Stang, A., Jöckel, K.-H. (2004). Studies with low response rates may be less biased than studies 

with high response rates. 

American Journal of Epidemiology 159 (2): 204-210. IF 4.9 

Bromen, K., Stang, A., Baumgardt-Elms, C., Stegmaier, C., Ahrens, W., Mets, K.A., 

Jöckel, K.- H. (2004). Testicular, other genital, and breast cancers in first-degree relatives 

of testicular cancer patients and controls. 

Cancer Epidemiol Biomarkers Prev 13 (8): 1316-1324. IF 4.5 

Hüsing, J., Zeschnigk, M., Boes, T., Jöckel, K.-H. (2003). Combining DNA expression with 

positional information to detect functional silencing of chromosomal regions. 

Bioinformatics 19 (18): 2335-2342 IF 5.7 

Jöckel, K.-H., Anastassiou, G., Schilling, H., Bornfeld, N., Horsthemke, B., Lohmann, R. D., 

Zeschnigk, M. (2003). Tumor classification based on gene expression profiling shows that uveal 

melanomas with and without monosomy 3 represent two distinct entities. 

Cancer Research 63: 2578-2584 IF 8.4


Klein-Hitpass, Ludger, PD Dr. rer. nat. 

Biochip-Labor, Institute for Cell Biology – Tumor Research 

6. Selected publications 2002 - 2008 

Duerig, J., Nueckel, H., Huettmann, A., Kruse, E., Hoelter, T., Halfmeyer, K., Fuehrer, A., 

Rudolph, R., Kalhori, N., Nusch, A., Deaglio, S., Malavasi, F., Moeroey, T., Klein-Hitpass, L., 

Duehrsen, U. (2002), Expression of ribosomal and translation-associated genes is correlated 

with a favorable clinical course in chronic lymphocytic leukaemia, 

Blood 101, 2748-55, 2002 IF 10.1 

Horsthemke B, Nazlican H, Hüsing J, Klein-Hitpass L, Claussen U, Michel S, Lich C, Gillessen- 

Kaesbach G, Buiting K (2003), Somatic mosaicism for maternal uniparental disomy 15 in a girl 

with Prader-Willi syndrome: confirmation by cell cloning and identification of candidate 

downstream genes, 

Hum Mol Genet. 12, 2723-2732, 2003 IF 7.8 

Dürig J, Nückel H, Cremer M, , Führer A, Halfmeyer K, Fandrey J, Möröy T, Klein-Hitpass L, 

Dührsen U (2003), ZAP-70 expression is a prognostic factor in chronic lymphatic leukemia, 

Leukemia 17, 2426-2434, 2003 IF 6.6 

Thomas H, Senkel S, Erdmann S, Arndt T, Turan G, Klein-Hitpass L, Ryffel GU. (2004), Pattern 

of genes influenced by conditional expression of the transcription factors HNF6, HNF4alpha and 

HNF1beta in a pancreatic beta-cell line. 

Nucleic Acids Res. 32, e150, 2004 IF 7.6 

Zeng H, Yücel R, Kosan C, Klein-Hitpass L, Möröy T. (2004), Transcription factor Gfi1 regulates 

self-renewal and engraftment of hematopoietic stem cells. 

EMBO J. 23, 4116-4125, 2004 IF 10.1 

Grasemann C, Gratias S, Stephan H, Schüler A, Schramm A, Klein-Hitpass L, Rieder H, 

Schneider S, Kappes F, Eggert A, Lohmann DR (2005), Gains and overexpression identify 

DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma, 

Oncogene 24, 6441-6449, 2005. IF 6.9 

Lucas B, Grigo K, Erdmann S, Lausen J, Klein-Hitpass L, Ryffel GU (2005). HNF4α reduces 

proliferation of kidney cells and affects genes deregulated in renal cell carcinoma, 

Oncogene 24, 6418-6431, 2005. IF 6.9 

Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, 

Warnat P, Brors B, Eils J, Eils R, Eggert A. (2005). Prediction of clinical outcome and biological 

characterization of neuroblastoma by expression profiling, 

Oncogene 24, 7902-7912, 2005. IF 6.9 

Hüttmann A, Klein-Hitpass L, Thomale J, Deenen R, Carpinteiro A, Nückel H, Ebeling P, 

Führer A, Edelmann J, Sellmann L, Dührsen U, Dürig J. Gene expression signatures separate 

B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 

expression status. 

Leukemia. 2006;20:1774-82. IF 6.6 

Gratias S, Rieder H, Ullmann R, Klein-Hitpass L, Schneider S, Bölöni R, Kappler M, Lohmann 

DR. Allelic loss in a minimal region on chromosome 16q24 is associated with vitreous seeding 

of retinoblastoma. 

Cancer Res. 2007;67:408-16. IF 8.4 

Dürig J, Bug S, Klein-Hitpass L, Boes T, Jöns T, Martin-Subero JI, Harder L, Baudis M, 

Dührsen U, Siebert R. Combined single nucleotide polymorphism-based genomic mapping 

and global gene expression profiling identifies novel chromosomal imbalances, mechanisms 

and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with 

inv(14)(q11q32). 

Leukemia. 2007;21:2153-63. IF 6.6

2. Coordinator: 

Prof. Dr. med. Winfried Siffert, 

Professor for Pharmacology and Toxicology, 

Director of the Institute of Pharmacogenetics 

6. Selected publications 2002-2008 

Lehnerdt GF, Franz P, Zaqoul A, Schmitz KJ, Grehl S, Lang S, Schmid KW, Siffert W, 

Jahnke K, Frey UH. Overall and Relapse-Free Survival in Oropharyngeal and Hypopharyngeal 

Squamous Cell Carcinoma Are Associated with Genotypes of T393C Polymorphism of the 

GNAS1 Gene. 

Clin Cancer Res. 2008; 14:1753-1758. IF 6,2 

Bachmann HS, Otterbach F, Callies R, Nückel H, Bau M, Schmid KW, Siffert W, Kimmig R. 

The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with 

a favorable outcome in lymph node negative invasive breast cancer patients. 

Clin Cancer Res. 2007; 13:5790-7. IF 6,2 

Nückel, H., Frey, U.H., Bau, M., Sellmann, L., Stanelle, J., Dürig, J., Jöckel, K.H., Dührsen, U., 

and Siffert, W. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene 

promoter with disease progression and survival in chronic lymphocytic leukaemia. 

Blood, 2006 IF 10,1 

Frey, U.H., Nückel, H., Sellmann, L., Bechtel, D., Küppers, R., Dürig, J., Dührsen, U. and 

Siffert, W. The GNAS1 T393C polymorphism is associated with disease progression and survival 

in chronic lymphocytic leukemia. 

Clin.Cancer Res 2006; 12:5686-92. IF 6,2 

Nückel., Frey, U. H., Sellmann, L., Bau, M., Dürig, J., Dührsen, U., and Siffert, W. Bax gene 

G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of association with 

incidence, disease stage and progression-free survival. 

Leukemia 20 (4):724, 2006. IF 5,8 

Frey, U. H., Lümmen, G., Jager, T., Jöckel, K. H., Schmid, K. W., Rübben, H., Müller, N., 

Siffert, W., and Eisenhardt, A. The GNAS1 T393C polymorphism predicts survival in patients 

with clear cell renal cell carcinoma. 

Clin.Cancer Res. 12:759-763, 2006. IF 6,2 

Frey, U. H., Alakus, H., Wohlschlaeger, J. Schmitz, K.J., Winde, G., van Calker, H.G., Jöckel, K.H. 

Siffert, W., and Schmid, K.W. GNAS1 T393C Polymorphism and Survival in Patients with 

Sporadic Colorectal Cancer. 

Clin.Cancer Res. 11 (14):5071-5077, 2005. IF 6,2 

Nückel, H., Frey, U. H., Dürig, J., Dührsen, U. and Siffert, W. Methylenetetrahydrofolate reductase 

(MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of 

leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia. 

Leukemia, 2004. IF 6,6 

Holtmann, G:, Siffert, W., Haag, S., Mueller, N., Langkafel, M., Senf, W., Zotz, R:, and Talley, N. J. 

G-protein beta3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. 

Gastroenterology 126 (4):971-979, 2004. IF 13,1 

Hauner, H., Meier, M., Jöckel, K. H., Frey, U.H., and Siffert, W. Prediction of successful weight 

reduction under sibutramine therapy through genotyping of the GNB3 C825T polymorphism. 

Pharmacogenetics 13, 453-459, 2003 IF 6,4 

Hauner, H., Meier, M., Jöckel, K. H., Frey, U. H., and Siffert, W. Prediction of successful weight 


Pharmacogenetics 13, 453-459, 2003 IF 6,4


Prof. Dr. med. Dipl.Chem. A.W. Rettenmeier 

Institute of Hygiene and Occupational Medicine 


Eckstein A, Quadbeck B, Müller G, Rettenmeier AW, Hoermann R, Mann K, Steuhl P, Esser J 

(2003): Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. 

Br J Ophthalmopathy 87: 773-776 IF 2,1 

Kleinsasser NH, Juchhoff J, Wallner BC, Bergner A, Harréus UA, Gamarra F, Bührlen M, 

Huber RM, Rettenmeier AW (2004): The use of mini-organ cultures of human upper aerodigestive 

tract epithelia in ecogenotoxicology. 

Mut Res 561: 63-73 IF 3,4 

Goebell PJ, Villanueva CM, Rettenmeier AW, Rübben H, Kogevinas M (2004): Environmental 

exposure, chlorinated drinking water, and bladder cancer. 

W J Urol 21: 424-432 IF 1,4 

Dopp E., Hartmann LM, Florea AM, Rettenmeier AW, Hirner AV (2004): Environmental distribution, 

analysis and toxicity of organometal(loid) compounds. 

Crit Rev Toxicol 34: 1-33 IF 2,5 

Dopp E, Hartmann LM, Florea AM, von Recklinghausen U, Pieper R, Shokouhi B, 

Rettenmeier AW, Hirner AV, Obe G (2004): Uptake of inorganic and organic derivatives of arsenic 

associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells. 

Toxicol Appl Pharmacol 201: 156-165 IF 2,9 

Dopp E, Hartmann LM, von Recklinghausen U, Florea AM, Rabieh S, Zimmermann U, Shokouhi B, 

Yadav S, Hirner AV, Rettenmeier AW (2005): Forced uptake of trivalent and pentavalent 

methylated and inorganic arsenic and its cyto-/genotoxicity in fibroblasts and hepatoma cells. 

Toxicol Sci 87: 46-56 IF 3,1 

Geh S, Yücel R, Duffin R, Albrecht C, Borm PJA, Armbruster L, Raulf-Heimsoth M, Brüning T, 

Hoffmann E, Rettenmeier AW, Dopp E (2006): Cellular uptake and cytotoxic potential of respirable 

bentonite particles with different quartz contents and chemical modifications. 

Arch Toxicol 80: 98-106 IF 1,6 

Dopp E, Hartmann LM, Florea AM, von Recklinghausen U, Rabieh S, Shokouhi B, Hirner AV, 

Rettenmeier AW (2006): Trimethylantimony dichloride causes genotoxic effects in Chinese hamster 

ovary cells after forced uptake. 

Toxicol in vitro 20: 1060-1065 IF 1,6 

Dopp E, Hartmann LM, von Recklinghausen U, Florea AM, Rabieh S, Shokouhi B, Hirner AV, 

Obe G, Rettenmeier AW (2007): The cyto- and genotoxicity of organotin compounds is dependent 

on the cellular uptake capability. 

Toxicology 232: 226-234 IF 2,1 

Dopp E, von Recklinghausen U, Hartmann LM, Stueckradt I, Pollok I, Rabieh S, Hao L, 

Nussler AK, Katier C, Hirner AV, Rettenmeier AW (2008): Subcellular distribution of inorganic and 

methylated arsenic compounds in human urothelial cells and human hepatocytes. 

Drug Metab Dispos. IF 3,7 

Michalke K, Schmidt A, Huber B, Meyer J, Sulkowski M, Hirner AV, Boertz J, Mosel F, 

Dammann P, Hilken G, Hedrich HJ, Dorsch M, Rettenmeier AW, Hensel R (2008): The role of 

intestinal microbiota in the transformation of bismuth and other metals and metalloids into volatile 

methyl and hydride derivatives in humans and mice. 

Appl Environ Microbiol 2008 Mar 31; [Epub ahead of print] IF 3,8

2. Coordinators 

PD Dr. Gero Hilken/Dr. Ralph Waldschütz 

Central Animal Facility 

6. Selected Publications 2002-2008 

Herborn CU, Waldschütz R, Lauenstein TC, Goyen M, Lauffer RB, Möröy T, Debatin JF, 

Ruehm SG. Contrast-enhanced magnetic resonance imaging (MS-325) in a murine model 

of systemic lupus erythematosus. 

Invest Radiol. 37: 464-9 (2002) IF 2,0 

Schmidt A, Marescau B, Böhm EA, Renema WK, Peco R, Das A, Steinfeld R, Chan S, 

Wallis J, Davidoff M, Ullrich K, Waldschütz R, Heerschap A, De Deyn PP, Neubauer S, 

Isbrandt D. Severely altered guanidine compound levels, disturbed body weight homeostasis and 

impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. 

Hum Mol Genet. 13: 905-21 (2004) IF 8,6 

Sinnegger-Brauns MJ, Hetzenauer A, Huber IG, Renstrom E, Wietzorrek G, Berjukov S, 

Cavalli M, Walter D, Koschak A, Waldschütz R, Hering S, Bova S, Rorsman P, Pongs O, 

Singewald N, Striessnig J J. Isoform-specific regulation of mood behavior and pancreatic 

beta cell and cardiovascular function by L-type Ca 2+ channels. 

J Clin Invest. 113:1430-9 (2004) IF 14,3 

Grüter B, Petter M, Egawa T, Laule-Kilian K, Aldrian CJ, Würch A, Ludwig Y, Fukuyama H, 

Wardemann H, Waldschütz R, Möröy T, Taniuchi I, Steimle V, Littman DR, Ehlers M. Runx3 

regulates integrin alpha E/CD103 and CD4 expression during development of CD4-/CD8+ T cells. 

J Immunol. 175:1694-705 (2005) IF 6,7 

Rosenberg J, Müller CH, Hilken G. Ultrastructural organization of the anal organs in the anal 

capsule of Craterostigmus tasmanianus Pocock, 1902 (Chilopoda, Craterostigmomorpha). 

J Morphol. 267:265-72 (2006) IF 1,7 

Wedemeyer C, Neuerburg C, Pfeiffer A, Heckelei A, von Knoch F, Hilken G, Brankamp J, 

Henschke F, von Knoch M, Löer F, Saxler G. Polyethylene particle-induced bone resorption 

in substance P-deficient mice. 

Calcif Tissue Int. 80:268-74. (2007) IF 2,2 

Wedemeyer C, Neuerburg C, Pfeiffer A, Heckelei A, Bylski D, von Knoch F, Schinke T, 

Hilken G, Gosheger G, von Knoch M, Löer F, Saxler G. Polyethylene particle-induced bone 

resorption in alpha-calcitonin generelated peptide-deficient mice. 

J Bone Miner Res. 22:1011-9. (2007) IF 6,2 

Michalke K, Schmidt A, Huber B, Meyer J, Sulkowski M, Hirner AV, Boertz J, Mosel F, 

Dammann P, Hilken G, Hedrich HJ, Dorsch M, Rettenmeier AW, Hensel R (2008): The role 

of intestinal microbiota in the transformation of bismuth and other metals and metalloids into 

volatile methyl and hydride derivatives in humans and mice. 

Appl Environ Microbiol 2008 Mar 31; [Epub ahead of print] IF 3,8


Prof. Dr. med. Jan Buer 

Institute of Medical Microbiology 


Reinwald, S., C. Wiethe, A. M. Westendorf, M. Breloer, M. Probst-Kepper, B. Fleischer, 

A. Steinkasserer, J. Buer, and W. Hansen. 2008. CD83 expression in CD4+ T cells modulates 

inflammation and autoimmunity. 

J. Immunol. (in press) IF 6,7 

Veldhoen, M., K. Hirota, A. M. Westendorf, J. Buer, L. Dumoutier, J. C. Renauld, and 

B. Stockinger. 2008. The aryl hydrocarbon receptor links T(H)17-cell-mediated autoimmunity 

to environmental toxins. 

Nature (epub ahead of print). IF 31 

Bohn, G., A. Allroth, G. Brandes, J. Thiel, E. Glocker, A. A. Schaffer, C. Rathinam, N. Taub, 

D. Teis, C. Zeidler, R. A. Dewey, R. Geffers, J. Buer, L. A. Huber, K. Welte, B. Grimbacher, 

and C. Klein. 2007. A novel human primary immunodeficiency syndrome caused by deficiency 

of the endosomal adaptor protein p14. 

Nat. Med. 13:38-45. IF 30,5 

Choudhury, A. R., Z. Ju, M. W. Djojosubroto, A. Schienke, A. Lechel, S. Schaetzlein, H. Jiang, 

A. Stepczynska, C. Wang, J. Buer, H. W. Lee, Z. T. von, A. Ganser, P. Schirmacher, 

H. Nakauchi, and K. L. Rudolph. 2007. Cdkn1a deletion improves stem cell function and lifespan 

of mice with dysfunctional telomeres without accelerating cancer formation. 

Nat. Genet. 39:99-1005. IF 26,5 

Hansen, W., A. M. Westendorf, S. Reinwald, D. Bruder, S. Deppenmeier, L. Groebe, 

M. Probst-Kepper, A. D. Gruber, R. Geffers, and J. Buer. 2007. Chronic antigen stimulation 

in vivo induces a distinct population of antigen-specific Foxp3 CD25 regulatory T cells. 

J. Immunol. 179:8059-68. IF 6,7 

He, F., J. Buer, A. P. Zeng, and R. Balling. 2007. Dynamic cumulative activity of transcription 

factors as a mechanism of quantitative gene regulation. 

Genome Biol. 8:R181.IF 7,2 

Blumenthal, A., S. Ehlers, J. Lauber, J. Buer, C. Lange, T. Goldmann, H. Heine, E. Brandt, 

and N. Reiling. 2006. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate 

inflammatory responses of human mononuclear cells induced by microbial stimulation. 

Blood 108:965-73. IF 10,1 

Fritzsching, B., N. Oberle, E. Pauly, R. Geffers, J. Buer, J. Poschl, P. Krammer, O. Linderkamp, 

and E. Suri-Payer. 2006. Naive regulatory T cells: a novel subpopulation defined by resistance 

toward CD95Lmediated cell death. 

Blood 108:3371-78. IF 10,1 

Huehn J, Siegmund K, Lehmann JC, Siewert C, Haubold U, Feuerer M, Debes GF, Lauber J, 

Frey O, Przybylski GK, Niesner U, de la Rosa M, Schmidt CA, Bräuer R, Buer J, Scheffold A, 

Hamann A.2004 Developmental stage, phenotype, and migration distinguish naive- and 

effector/memory-like CD4+ regulatory T cells. 

J Exp Med. 199: 303-13. IF 15,3f 

Buer J, Balling R. 2003 Mice, microbes and models of infection. 

Nat Rev Genet. 4:195-205. IF 25,6

2. Director 

Prof. Dr. Karl-Heinz Jöckel 

Director, Institute of Medical Informatics, Biometrics and Epidemiology 

6. Selected publications 2006 – 2008: 

Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, Urbanski K, Seeber S, 

Scheulen ME. (2006) Risk factors for venous thromboembolic events in cancer patients. 

Ann Oncol. 17:297-303 IF 4.3 

Neuhäuser M, Lehmann N, Nonnemacher M, Stausberg J (2006): An attempt at data 

verification in the EACTS Congenital Database: data before and after verification differ 

significantly. 

Eur J Cardiothorac Surg 30: 691. IF 1.8 

Stausberg J, Lehmann N, Kaczmarek D, Stein M. Reliability of diagnoses coding with 

ICD-10. (2008) 

Int J Med Inform. 77:50-7. IF 1.2

2. Coordinator: Max E. Scheulen, MD, PhD 

Prof. Dr. med. Dipl.-Biochem. Max E. Scheulen 

Clinical Phase I-Unit and Pharmacology of 

Antineoplastic Substances 


Kruijtzer, C. M. F., Schellens, J. H. M., Mezger, J., Scheulen, M. E., Keilholz, U., Beijnen, J. H., 

Rosing, H., Mathôt, R. A. A., Marcus, S., van Tinteren, H., Baas, P.: A phase II and pharmacologic 

study of weekly oral paclitaxel plus cyclosporin A in patients with advanced 

non-small cell lung cancer. 

J. Clin. Oncol. 20, 4508-4516 (2002) IF 9,8 

Mross K, Richly H, Schleucher N, Korfee S, Tewes M, Scheulen ME, Seeber S, Beinert T, 

Schweigert M, Sauer U, Unger C, Behringer D, Brendel E, Haase CG, Voliotis D, Strumberg D. 

A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, 

as a daily infusion in patients with advanced solid tumors. 

Ann Oncol. (2004) 15:1284-94. IF 4,3 

Schmittel A, Scheulen ME, Bechrakis NE, Strumberg D, Baumgart J, Bornfeld N, Foerster MH, 

Thiel E, Keilholz U. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with 

metastatic uveal melanoma. 

Melanoma Res. (2005) 15:205-7. IF 2,1 

Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., 

Brendel, E., Voliotis, D., Haase, C. G., Schwartz, B., Awada, A., Voigtmann, R., Scheulen, 

M. E., Seeber, S.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and 

vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced 

refractory solid tumors. 

J. Clin. Oncol. 23, 965-972 (2005) IF 9,8 

Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, 

Postma TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy 

worsening. 

Neurology. (2005) 64: 1076-7. IF 5,7 

Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., 

Hess, D., Morant, R., Semiglazov, V., Borner, M., Salzberg, M., Ostapenko, V., Illiger, H. J., 

Behringer, D., Bardy-Bouxin, N., Boni, J., Kong, S., Cincotta, M., Moore, L.: Phase 2 study of 

temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally 

advanced or metastatic breast cancer. 

J. Clin. Oncol. 23, 5314-5322 (2005). IF 9,8 

Richly, H., Henning, B. F., Kupsch, P., Passarge, K., Grubert, M., Hilger, R. A., Christensen, O., 

Brendel, E., Schwartz, B., Ludwig, M., Flashar, C., Voigtmann, R., Scheulen, M. E., Seeber, S., 

Strumberg, D.: Results of a phase I trial of sorafenib (BAY 43-9006) in combination with 

doxorubicin in patients with refractory solid tumors. 

Ann. Oncol. 17, 866-873 (2006). IF 4,3 

Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, Urbanski K, Seeber S, 

Scheulen ME. Risk factors for venous thromboembolic events in cancer patients. 

Ann Oncol. (2006) 17:297-303. IF 4,3 

Rattmann I, Kleff V, Sorg UR, Bardenheuer W, Brueckner A, Hilger RA, Opalka B, Seeber S, 

Flasshove M, Moritz T.: ene transfer of cytidine deaminase protects myelopoiesis from cytidine 

analogs in an in vivo murine transplant model. 

Blood 108, :2965-2971 (2006). IF 10.1 

Steinbild, S., Mross, K., Frost, A., Morant, R., Gillessen, S., Dittrich, C., Strumberg, D., Hochhaus, 

A., Hanauske, A., Edler, L., Burkholder, I., Scheulen, M. E.: A clinical phase II study with sorafenib 

in patients with hormone-refractory prostate cancer – a study of the CESAR Central European 

Society for Anticancer Drug Research-EWIV. 

Brit. J. Cancer 97:1480-1485 (2007). IF 4.1

Dr. Alexander Schramm 

Childrens Hospital, Oncology Lab 

6. Selected Publications (2002-2008) 

Boller D, Schramm A, Doepfner KT, Shalaby T, von Bueren AO, Eggert A, Grotzer MA, 

Arcaro A. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival 

in neuroblastoma cells. 

Clin Cancer Res. 2008 Feb 15;14(4):1172-81. IF 7,7 

Zeng Y, Huebener N, Fest S, Weixler S, Schroeder U, Gaedicke G, Xiang R, Schramm A, 

Eggert A, Reisfeld RA, Lode HN. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma 

microenvironment induces eradication of metastases mediated by T cells and natural killer cells. 

Cancer Res. 2007 Mar 1;67(5):2331-8. IF 8,3 

Dürig J, Ebeling P, Grabellus F, Sorg U, Möllmann M, Schütt P, Göthert J,Sellmann L, 

Flasshove M, Dührsen U, Moritz T. A novel nonobese diabetic/severe combined immunodeficient 

xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the 

disease. 

Cancer Res. 2007 67:8653-61. IF 7,7 

Schramm A, Vandesompele J, Schulte JH, Dreesmann S, Kaderali L, Brors B, Eils R, 

Speleman F, Eggert A. Translating expression profiling into a clinically feasible test to predict 

neuroblastoma outcome. 

Clin Cancer Res. 2007 Mar 1;13(5):1459-65. IF 6,5 

Becker J, Erdlenbruch B, Noskova I, Schramm A, Aumailley M, Schorderet DF, Schweigerer L. 

Keratoepithelin suppresses the progression of experimental human neuroblastomas. 

Cancer Res. 2006 66(10):5314-21. IF 8,3 

Sitek B, Apostolov O, Stuhler K, Pfeiffer K, Meyer HE, Eggert A, Schramm A. Identification of 

dynamic proteome changes upon ligand activation of Trk-receptors using two-dimensional 

fluorescence difference gel electrophoresis and mass spectrometry. 

Mol Cell Proteomics. 2005 4(3):291-9 IF 9,6 

Nückel H, Rebmann V, Dürig J, Dührsen U, Grosse-Wilde H: HLA-G expression is associated 

with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukaemia. 

Blood 2005; 105:1694-8 IF 10.1 

Röth A, Baerlocher GM, Schertzer M, Elizabeth C, Dührsen U, Lansdorp PM: Telomere loss, 

senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT. 

Blood 2005; 106:43-50. IF 10.1 

Dürig J, Nückel H, Hüttmann A, Kruse E, Hölter T, Halfmeyer K, Führer A, Rudolph R, 

Kalhori N, Nusch A, Deaglio S, Malavasi F, Möröy T, Klein-Hitpass L, Dührsen U: Expression of 

ribosomal and translationassociated genes is correlated with a favorable clinical course in CLL. 

Blood 2003; 101:2748-55 IF 10.1

2. Coordinators: 

A. Bockisch (Biographical Sketch see DCP 9) 

M. Forsting, M. Ladd, J. Stattaus, Dept. of Radiology 

6. Selected publications 

Veit-Haibach P, Kuehle CA, Beyer T, Stergar H, Kuehl H, Schmidt J, Börsch G, Dahmen G, 

Barkhausen J, Bockisch A, Antoch G. Diagnostic accuracy of colorectal cancer staging with 

whole-body PET/CT colonography. 

JAMA. 2006;296:2590-600. IF 23.3 

Veit P, Kühle C, Beyer T, Kühl H, Herborn CU, Borsch G, et al. Whole body positron 

emission tomography/computed tomography (PET/CT) tumour staging with integrated 

PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. 

Gut. 2006;55:68-73. IF 6.6 

Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, et al. Value of 

18F-fluoro-2-deoxy-Dglucose- positron emission tomography/computed tomography in 

non-small-cell lung cancer for prediction of pathologic response and times to relapse after 

neoadjuvant chemoradiotherapy. 

Clin Cancer Res. 2006;12:97-106. IF 5.6 

Beyer T, Bockisch A, Kühl H, Martinez MJ. Whole-Body 18F-FDG PET/CT in the Presence of 

Truncation Artifacts. 

J Nucl Med. 2006;47:91-9. IF 5.4 

Antoch G, Saoudi N, Kühl H, Dahmen G, Müller SP, Beyer T, et al. Accuracy of 

whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography 

and computed tomography (FDGPET/ CT) for tumor staging in solid tumors: comparison with 

CT and PET. 

J Clin Oncol. 2004 ;22:4357- 68. IF 9.8 

Antoch G, Kanja J, Bauer S, Kühl H, Renzing-Köhler K, Schütte J, et al. Comparison of PET, CT, 

and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with 

gastrointestinal stromal tumors. 

J Nucl Med. 2004;45:357-65. IF 5.4 

Bengel FM, Anton M, Richter T, Simoes MV, Haubner R, Henke J, Erhardt W, Reder S, Lehner T, 

Brandau W, Boekstegers P, Nekolla S G, Gansbacher B, Schwaiger M. Noninvasive imaging of 

transgene expression by use of positron emission tomography in a pig model of myocardial gene 

transfer. 

Circulation. 2003;108:2127-33. IF12.5 

Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Göhde SC, et al. Whole-body dual-modality 

PET/CT and whole-body MRI for tumor staging in oncology. 

JAMA. 2003;290:3199-206. IF 24.8 

Herrmann BL, Saller B, Janssen OE, Gocke P, Bockisch A, Sperling H, et al. Impact of 

estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel 

mutation in the CYP19 gene. 

J Clin Endocrinol Metab. 2002 Dec;87(12):5476-84. IF 5.8 

Antoch G, Egelhof T, Korfee S, Frings M, Forsting M, Bockisch A. Recurrent schwannoma: 

diagnosis with PET/CT. 

Neurology. 2002 Oct 22;59(8):1240. IF 5.8


Prof. Dr. med. Martin Stuschke, 

Director, Dept. of Radiotherapy 

6. Selected publications 

Pöttgen C, Eberhardt W, Grannass A, Korfee S, Stüben G, Teschler H, Stamatis G, Wagner H, 

Passlick B, Petersen V, Budach V, Wilhelm H, Wanke I, Hirche H, Wilke HJ, Stuschke M. 

Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with 

neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. 

J Clin Oncol. 2007;25:4987-92. IF 13,6 

Sak A, Fegers I, Groneberg M and Stuschke M. The effect of separase depletion on ionising 

radiation induced cell-cycle checkpoints and survival in human lung cancer cell lines. 

Cell Prolif. 2008, in press. IF 4.5 

Eberhardt W, Pöttgen C, Stuschke M. Chemoradiation paradigm for the treatment of lung cancer. 

Nat Clin Pract Oncol. 2006;3:188-99. New 

Pottgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, 




Clin Cancer Res. 2006;12:97-106 IF 5.6 

Sak A, Stueben G, Groneberg M, Bocker W, Stuschke M. Targeting of Rad51-dependent 

homologous recombination: implications for the radiation sensitivity of human lung cancer 

cell lines. 

Br J Cancer. 2005; 28:1089-97. IF 3.7 

Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, 

Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery 

in patients with locally advanced squamous cell carcinoma of the esophagus. 

J Clin Oncol. 2005;23:2310-7. IF 9.8 

Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, 

Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD. 

Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more 

effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally 

advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group 

of the German Cancer Society 95-06 Prospective Randomized Trial. 

J Clin Oncol. 2005;23:1125-35. IF 9.8 

Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stuschke M, Thews O, Vaupel P. 

Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human 

tumors in nude mice. 

Int J Radiat Oncol Biol Phys. 2003; 55:1358-62. IF 4.3 

Marnitz S, Stuschke M, Bohsung J, Moys A, Reng I, Wurm R, Budach V. Intraindividual 

comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy 

in the therapy of locally advanced non-small cell lung cancer a planning study. 

Strahlenther Onkol 2002;178: 651-8. IF 3.1 

Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S. Update 

on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental 

predispositions, clinical manifestations, and therapy. 

Lancet Infect Dis 2002; 2: 281-92. IF 10.8 

Sak A, Stuschke M, Wurm R, Schroeder G, Sinn B, Wolf G, Budach V. Selective inactivation of 

DNAdependent protein kinase with antisense oligodeoxynucleotides: consequences for the 

rejoining of radiation-induced DNA double-strand breaks and radiosensitivity of human cancer 

cell lines. 

Cancer Res 2002; 62: 6621-4. IF 8.4 

Stuschke M, Sak A, Wurm R, Sinn B, Wolf G, Stuben G, Budach V. Radiation-induced apoptosis in 

human non-small-cell lung cancer cell lines is secondary to cell-cycle progression beyond 

the G2-phase checkpoint.

Int J Radiat Biol 2002; 78: 807-19. IF 2.1 

Pottgen C, Eberhardt W, Bildat S, Stuben G, Stamatis G, Hillejan L, Sohrab S, Teschler H, 


and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung 

cancer (stages IIIa/IIIb): a pilot phase I/II trial. 

Ann Oncol 2002; 13: 403-11. IF 4.3


Prof. Dr. med. W.Siffert and Prof. Dr. med. N. Scherbaum 


Nückel, H., Frey, U. H., Bau, M., Sellmann, L., Stanelle, J., Dürig, J., Jöckel, K. H., Dührsen, U., 

and Siffert, W. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene 

promoter with disease progression and survival in chronic lymphocytic leukaemia. 

Blood, 2007, 290-97 IF 10,1 

Frey, U. H., Nückel, H., Sellmann, L., Bechtel, D., Küppers, R., Dürig, J., Dührsen, U. and 

Siffert, W. The GNAS1 T393C polymorphism is associated with disease progression and 

survival in chronic lymphocytic leukemia. 

Clin.Cancer Res, 2006 12: 5686-92 IF 5,6 

Nückel, H., Frey, U. H., Sellmann, L., Bau, M., Dürig, J., Dührsen, U., and Siffert, W. 

Bax gene G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of 

association with incidence, disease stage and progression-free survival. 

Leukemia 20 (4):724, 2006. IF 5,8 

Frey, U. H., Lümmen, G., Jager, T., Jöckel, K. H., Schmid, K. W., Rübben, H., Müller, N., 

Siffert, W., and Eisenhardt, A. The GNAS1 T393C polymorphism predicts survival in patients 

with clear cell renal cell carcinoma. 

Clin.Cancer Res. 12 (3 Pt 1):759-763, 2006. IF 5,6 

Frey, U. H., Alakus, H., Wohlschlaeger, J. Schmitz, K.J., Winde, G., van Calker, H.G., 

Jöckel, K.H. Siffert, W., and Schmid, K.W. GNAS1 T393C Polymorphism and Survival in patients 

with Sporadic Colorectal Cancer. 

Clin.Cancer Res. 11 (14):5071-5077, 2005. IF 5,6 

Nückel, H., Frey, U. H., Dürig, J., Dührsen, U. and Siffert, W. Methylenetetrahydrofolate reductase 

(MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of 

leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia. 

Leukemia, 2004. IF 6,6 

Holtmann, G:, Siffert, W., Haag, S., Mueller, N., Langkafel, M., Senf, W., Zotz, R:, and Talley, N. J. 

G-protein beta3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. 

Gastroenterology 126 (4):971-979, 2004. IF 13,1 



Pharmacogenetics 13, 453-459, 2003 IF 6,4 



Pharmacogenetics 13, 453-459, 2003 IF 6,4


Prof. Dr. med. Erich Gulbins/ 

Dept. of Molecular Biology 


Grassmé H., Jendrossek V., Riehle A., von Kürthy G., Berger J., Schwarz H., Weller M., 

Kolesnick R., Gulbins E. (2003). Host defense against P. aeruginosa requires 

ceramide-rich membrane rafts. 

Nature Medicine 9, 322-330. IF 30.6 

Grassmé H., Cremesti A., Kolesnick R., Gulbins E. (2003). Ceramide-mediated clustering is 

required for CD95-DISC formation. 

Oncogene 22, 5457-5470. IF 6,4 

Göggel R., Winoto-Morbach S., Vielhaber G., Imai Y., Lindner K., Brade L., Brade H., Ehlers S., 

Slutsky A.S., Schütze S., Gulbins E., Uhlig S. (2004). Pulmonary edema: a novel effector function 

for acid sphingomyelinase and ceramide. 

Nature Medicine 10, 155-160. IF 30.6 

Szabo I., Bock J., Jekle A., Soddemann M., Adams C., Lang F., Zoratti M., Gulbins E. (2005). 

A novel potassium channel in lymphocyte mitochondria. 

J. Biol. Chem. 280, 12790-12798. IF 6.5 

Dumitru C., Gulbins E. (2006). TRAIL/DR5-induced apoptosis by the acid sphingomyelinase, 

ceramide and ceramide-enriched membrane platforms. 

Oncogene, 25, 5612-5625. IF 6.4 

Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, 

Klarl BA, Rübben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, 

Erhardt A, Häussinger D, Gulbins E, Lang F. (2007) Liver cell death and anemia in Wilson 

disease involve acid sphingomyelinase and ceramide. 

Nature Medicine 13:164-70. IF 30,6 

Rebillard A, Tekpli X, Meurette O, Sergent O, LeMoigne-Muller G, Vernhet L, Gorria M, 

Chevanne M, Ch i t M K i B C ill L G lbi E L di G DDi h B it l MT (2007) 

Christmann M, Kaina B, Counillon L, Gulbins E, Lagadic-Gossmann D, Dimanche-Boitrel MT. 

(2007) Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in 

human colon cancer cells. 

Cancer Res. 67:7865-74. IF 8,7 

Teichgräber V., Ulrich M., Endlich N., Riethmüller J., Wilker B., De Oliveira-Munding C., 

van Heeckeren A. M., Barr M. L., von Kurthy G., Schmid K. W., Weller M., Tümmler B., Lang F., 

Grassme H., Döring G. Gulbins E. (2008). Ceramide accumulation mediates inflammation, cell 

death and infection susceptibility in cystic fibrosis. 

Nature Medicine. 14, 382-91 IF 30,6 

Eisenhardt A, Frey U, Tack M, Rosskopf D, Lümmen G, Rübben H, Siffert W. Expression analysis 

and potential functional role of the CXCR4 chemokine receptor in bladder cancer. 

Eur Urol. 2005;47:111- 117. 

Frey UH, Eisenhardt A, Lümmen G, Rübben H, Jöckel KH, Schmid KW, Siffert W. The T393C 

polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. 

Cancer Epidemiol Biomarkers Prev. 2005;14:871-7. IF 2.6 IF 4.5


Prof. Dr. med. Jan Buer 

Institute of Medical Microbiology 

Prof. Dr. Dirk Schadendorf 

Director, Department of Dermatology, 


Bukur J., Rebmann V., Grosse-Wilde H., Luboldt H., Rübben H., Drexler I., Sutter G., Huber Ch., 

Seliger B.(2003) Functional role of HLA-G up-regulation in renal cell carcinoma. 

Cancer Res 63 : 4107-4111 IF 8.6 

Andersen M. H., Festerle J., Ugurel S., Reker S., Houben R., Guldberg P., Berger T. G., 

Schadendorf D., Trefzer U., Broecker E.-B., Straten P. t., Rapp U. R. and Becker J. C. (2004). 

Immunogenicity of constitutively active V599EBRaf. 

Cancer Res 64: 5456-5460. IF 8.6 

Huber C, Bobek N, Kuhball J, Thaler S, Hoffarth S, Huber Ch, Theobald M, Schuler M. (2005) 

Inhibitors of apoptosis confer resistance to tumor suppression by adoptively transplanted cytotoxic 

T lymphocytes in vitro and in vivo. 

Cell Death Differ. 12:317-325, IF 7,8 

Rohn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, Kropshofer H (2005). 

A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of 

a melanotransferrin helper T-cell epitope. 

Cancer Res. 65(21):10068-78. IF 7.6 

Nückel H, Rebmann V, Dürig J, Dührsen U, Grosse-Wilde H. (2005). HLA-G expression is 

associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukaemia. 

Blood 105,1694-8. IF 10.1 

Paschen A, Song M, Osen W, Nguyen X D, Mueller-Berghaus J, Fink D, Daniel N, 

Donzeau M, Nagel W, Kropshofer H, Schadendorf D. (2005). Detection of spontaneous 

CD4+ T-cell responses in Melanoma patients against a Tyrosinase-related protein-2 – 

Derived epitope identified in HLA-DRB1 *0301 transgenic mice. 

Clin Cancer Res 11 (14): 5241-5247 IF 7.6 

Müller-Berghaus J, Ehlert K, Ugurel S, Umansky V, Bucur M, Schirrmacher V, Beckhove P, 

Schadendorf D. (2006). Melanoma-reactive T cells in the bone marrow of melanoma patients: 

Association with disease stage and disease duration. 

Cancer Res: 66(12):5997-6001. IF 7.6 

Sun Y, Stevanovic, S, Song M, Schwantes A, Kirkpatrick, CJ, Schadendorf D, Cichutek K (2006). 

The Kinase Insert Domain-Containing Receptor Is a Tumor Endothelia-Associated Antigen 

Recognized by Human Cytotoxic T Lymphocytes. 

Blood. 107(4):1476-83. Epub 2005 Oct 18. IF 10.4 

Marques CA, Hähnel PS, Wölfel C, Thaler S, Huber Ch, Theobald M, Schuler M (2008). An 

immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte – 

mediated tumor suppression. 

Blood 11: 1413-1419, 2008. IF 10,2 

Hoffarth S, Zitzer A, Wiewrodt R, Hähnel PS, Beyer V, Kreft A, Biesterfeld S, Schuler M. (2008) 

pp32/PHAPI determines the apoptosis response of non-small-cell lung cancer. 

Cell Death Differ.15:161-70. IF 7,8 

Hähnel PS, Thaler S, Antunes E, Huber Ch, Theobald M, Schuler M. Targeting AKT signaling 

sensitizes cancer to cellular immunotherapy. 

Cancer Res. In press. IF 8,6


Prof. Michael Ehrmann 

ZMB 


Krojer, T., Sawa, J., Schäfer, E., Saibil, H. R., Ehrmann, M. and T. Clausen. 2008 Structural basis 

for the regulated protease and chaperone function of DegP. 

Nature, in press IF 27 

Krojer, T., Pangerl, K., Kurt, J., Sawa, J., Stingl, C., Mechtler, K., Huber, R., Ehrmann, M., and 

T. Clausen (2008) The interplay of PDZ and protease domain of DegP ensures efficient 

elimination of misfolded proteins. 

Proc. Natl. Acad. Sci. USA, in press IF 10 

Meltzer, M, Hasenbein, S., Hauske, P., Kucz, N., Merdanovic, M., Grau, S., Beil, A., Jones, D., 

Krojer, T., Clausen, T., Ehrmann, M. and M. Kaiser (2008) Allosteric activation of HtrA protease 

DegP by stress signals in bacterial protein quality control. 

Angew Chem. Int. Ed. Engl., 47:1332-1334 IF 10 

Hasselblatt, H., Kurzbauer, R., Wilken, C., Krojer, T., Sawa, J., Kurt, J., Kirk, R., Hasenbein, S., 

Ehrmann, M., and T. Clausen (2007) Regulation of the σE stress response by DegS: How the 

PDZ domain keeps the protease inactive in the resting state and allows integration of different 

OMP-derived stress signals upon folding stress. 

Genes Dev. 21: 2659-2670 IF 15 

Hasenbein, S., Merdanovic, M. and M. Ehrmann (2007) Determinants of regulated proteolysis 

in signal transduction. 

Genes Dev. 21:6-10 IF 15 

Chien, J., Aletti, G., Baldi, A., Catalano, V., Muretto, P., Keeney, G.L., Kalli, K.R., Staub, J., 

Ehrmann, M., Cliby, W.A., Lee, Y.K., Bible, K.C., Hartmann, L.C., Kaufmann, S.H. and 

V. Shridhar (2006) Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. 

J. Clin. Invest. 116: 1994-2004 IF 15 

Grau, S. Baldi, A., Bussani, R., Tian, X., Stefanescu, R., Przybylski, M., Shridhar, V., 

Clausen, T. and M. Ehrmann. (2005) Implications of human HtrA1 in amyloid precursor protein 

processing. 

Proc. Natl. Acad. Sci. USA 102:6021-6026 IF 10 

Henrichs, T., Mikhaleva, N., Conz, C., Deuerling, Boyd, D., E., Zelasny, A., Bibi, E., Ban, N. 

and M. Ehrmann. (2005) Target-directed proteolysis at the ribosome. 

Proc. Natl. Acad. Sci. USA 02:4246-4251 IF 10 

Blankenfeldt, W., Kuzin, A.P., Skarina, T., Tong, L., Bayer, P., Janning, P., Thomashow, L.S., 

and Mavrodi, D.V. (2004) Structure and function of phenazine-biosynthesis protein PhzF from 

Pseudomonas fluorescens 2-79. 

PNAS, 101, 16431-16436. IF 10 

Harjes S, Bayer P, Scheidig AJ (2005) The crystal structure of human PAPS synthetase 1 

reveals asymmetry in substrate binding. 

J Mol Biol. 347:623-35. IF 7 

Wilken, C., Kitzing, K., Kurzbauer, R., Ehrmann, M. and T. Clausen (2004) Crystal structure 

of the DegS stress sensor: How a PDZ domain recognizes misfolded protein and activates 

a protease domain. 

Cell 117:483-494 IF 28 

Eser, M., and M. Ehrmann (2003) SecA-dependent quality control of intracellular protein 

localisation. 

Proc. Natl. Acad. Sci. USA 100: 13231-13234 IF 10 

Clausen, T, Southan, C. and Ehrmann, M (2002) The HtrA family of proteases, implications 

for protein composition and cell fate.

Mol. Cell 10:443-455 IF 17 

Krojer, T, Garrido-Franco, M, Huber, R., Ehrmann, M and Clausen, T. (2002) Crystal structure 

of DegP (HtrA) reveals a new protease-chaperone machine. 

Nature 416: 455-459 IF 32 

Beerenwinkel N, Däumer M, Sing T, Rahnenfuhrer J, Lengauer T, Selbig J, Hoffmann D, 

Kaiser R: Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. 

J Infect Dis. 2005 Jun 1;191(11):1953-60. IF 5.4 

Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, Korn K, Selbig J: 

Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting 

phenotype from genotype. 

Proc Natl Acad Sci U S A. 2002; 99:8271-6. IF 9.6 

Beerenwinkel N, Däumer M, Oette M, Korn K, Hoffmann D, Kaiser R, Lengauer T, Selbig J, 

Walter H. Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. 

Nucleic Acids Res. 2003 Jul 1;31(13):3850-5. IF 6.3


Prof. Dr. med. Erich Gulbins 

Dept. of Molecular Biology 

6. Selected Publications 2002-2008 (Publications E. Gulbins see TRU 5) 

Probst B, Rock R, Gessler M, Vortkamp A, Püschel AW. The rodent Four-jointed ortholog Fjx1 

regulates dendrite extension. 

Dev Biol. 2007;312:461-70. IF 5.4 

Koziel, L., Wuelling, M., Schneider, S., Vortkamp, A. (2005). Gli3 has repressing and activating 

functions downstream of Ihh in regulating two distinct steps of chondrocyte differentiation 

Development 132, 5249-60. IF 7.6 

Koziel, L., Kunath, M., McMahon, A.P., Kelly O.G. Vortkamp A. (2004) Ext1 dependent heparan 

sulfates regulate the range of Ihh signaling during endochondral ossification. 

Dev Cell 6, 801-13. IF 14.6 

Minina, E., Kreschel, C., Naski, M.C., Ornitz, D.M. and Vortkamp, A. (2002). Interaction of FGF, 

Ihh/Pthlh and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. 

Dev Cell 3, 439-449. IF 14.6


Prof. Dr. med. Joachim Fandrey 

Institute of Physiology 


Stolze I., Berchner-Pfannschmidt U., Freitag P., Frede S., Wotzlaw C., Acker H., Fandrey J. (2002). 

Hypoxia inducible erythropoitin gene expression in human neuroblastoma cells. 

Blood 100: 2623-2628. IF 10,1 

Shibata J., Hasegawa J., Siemens H.-J., Wolber E.M., Dibbelt L., Li D., Katschinski D.M., 

Fandrey J., Jelkmann W., Gassmann M., Wenger R.H., Wagner K.F. (2003). Hemostasis and 

coagulation at a hematocrit of 0.85: functional consequences of erythrocytosis. 

Blood 101: 4416-4422 IF 10,1 

Metzen E., Berchner-Pfannschmidt U., Stengel P., Marxen J.H., Stolze I., Klinger M., Huang W.Q., 

Wotzlaw C., Hellwig-Bügel T., Jelkmann W., Acker H., Fandrey J. (2003). Intracellular localisation 

of human HIF-1 alpha hydroxylase: implications for oxygen sensing. 

J Cell Sci. 116: 1319-26 IF 6,9 

Liu Q., Berchner-Pfannschmidt U., Möller U., Brecht M., Wotzlaw C., Acker H., Jungermann K., 

Kietzmann T. (2004). A Fenton reaction at the endoplasmic reticulum is involved in the redox 

control of hypoxia-inducible gene expression. 

Proc Natl Acad Sci USA 101: 4302-7 IF 10,5 

Berchner-Pfannschmidt U., Petrat F., Doege K., Trinidad B., Freitag P., Metzen E., de Groot H., 

Fandrey J. (2004). Chelation of cellular calcium modulates hypoxia-inducible gene expression 

through activation of Hypoxia-Inducible Factor-1 alpha. 

J Biol Chem. 279: 44976-44986. IF 6,4 

Frede, S., Freitag, P., Otto, T., Heilmaier, C., Fandrey, J. (2005). The proinflammatory cytokine IL- 

1β and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells 

through HIF-1 activation. 

Canc. Res. 65:4690-4697 IF 8,6 

Wotzlaw C, Otto T, Berchner-Pfannschmidt U, Metzen E, Acker H, Fandrey J (2007). Optical 

analysis of the HIF-1 complex in living cells by FRET and FRAP. 

FASEB J. 21: 700-707 IF 6,7 

Berchner-Pfannschmidt U, Yamac H, Trinidad B, Fandrey J. (2007) Nitric oxide modulates oxygen 

sensing by hypoxia-inducible factor 1-dependent induction of prolyl hydroxylase 2. 

J Biol Chem. 282:1788-96. IF 6,4 

Otto T, Fandrey J (2008). Thyroid hormone induces Hypoxia Inducible Factor 1{alpha} gene 

expression through TR{beta}/RXR{alpha} dependent activation of Hepatic Leukemia Factor. 

Endocrinology 149:2241-50 IF 5,2


Iliakis, George, Prof. Dr. phil. nat. 

University of Duisburg-Essen, Medical School, 

Institute for Medical Radiation Biology 

6. Selected Publications 2002 – 2008 

Buschfort-Papewalis C, Moritz T, Liedert B, Thomale J (2002), Down-regulation of DNA repair 

in human CD34(+) progenitor cells corresponds to increased drug sensitivity and apoptotic 

response. 

Blood 100:845-53 IF 10.2 

Wang X, Khadpe J, Hu B, Iliakis G, Wang Y.(2003) An over-activated ATR/CHK1 pathway is 

responsible for the prolonged G2 accumulation in irradiated AT cells. 

J Biol Chem. 278: 30869- 30874 IF 6.5 

Wang H, Perrault AR, Takeda Y, Qin W, Wang H, Iliakis G (2003).: Biochemical evidence for 

Ku-independent backup pathways of NHEJ. 

Nucleic Acids Res. 31: 5377-5388 IF 6.6 

Iliakis G, Wang Y, Guan J, Wang H. (2003) DNA damage checkpoint control in cells exposed 

To ionizing radiation, 

Oncogene 22: 5834-5847 IF 6.5 

Wang H, Boecker W, Wang H, Wang X, Guan J, Thompson LH, Nickoloff JA, Iliakis G. (2004) 

Caffeine inhibits homology-directed repair of I-SceI-induced DNA double-strand breaks. 

Oncogene 23, 824-834 IF 6.5 

Wang H, Rosidi B, Perrault R, Wang M, Zhang L, Windhofer F, Iliakis G (2005) DNA Ligase III 

As a Candidate Component of Backup Pathways of Nonhomologous End Joining. 

Cancer Res. 65: 4020-4030 IF 8.6 

Martin M, Genesca A, Latre L, Jaco I, Taccioli GE, Egozcue J, Blasco MA, Iliakis G, Tusell L, 

(2005) Postreplicative joining of DNA double-strand breaks causes genomic instability in 

DNAPKcs- deficient mouse embryonic fibroblasts. 


Terzoudi, GI, Manola KN, Pantelias GE, Iliakis G (2005) Checkpoint Abrogation in G2 

Compromises Repair of Chromosomal Breaks in Ataxia Telangiectasia Cells. 


Liedert B, Pluim D, Schellens J, Thomale J. (2006), Adduct-specific monoclonal antibodies for 

the measurement of cisplatin-induced DNA lesions in individual cell nuclei. 

Nucleic Acids Res. 34: e47, 1-12 IF 7.3 

Wang M, Wu W, Wu W, Rosidi R, Zhang L, Wang H, Iliakis G (2006) PARP-1 and Ku compete 

for repair of DNA double strand breaks by distinct NHEJ pathways. 

Nucleic Acids Res. 2006, 34: 6170-6182. IF 6,6 

Rosidi B, Wang M, Wu W, Sharma A, Wang H, Iliakis G (2008) Histone H1 functions as a 

stimulatory factor in backup pathways of NHEJ. 

Nucleic Acids Res. 36: 1610-1623 IF 6,6


Prof. Dr. Ann Elizabeth Ehrenhofer-Murray 

Zentrum für Medizinische Biotechnologie (ZMB) 

Prof. Dr. Bernhard Horsthemke 

Institut für Humangenetik 


Teller K, Solovei I, Buiting K, Horsthemke B, Cremer T (2007) Maintenance of imprinting and 

nuclear architecture in cycling cells. 

Proc Natl Acad Sci USA, 104:14970-14975 IF 10,5 

Horsthemke B (2007) Heritable germline epimutations in humans. 

Nat Genet 39:573-574 IF 26.5 

Fischer S, Lüdecke HJ, Wieczorek D, Böhringer S, Gillessen-Kaesbach G, Horsthemke B (2006) 

Histone acetylation dependent allelic expression imbalance of BAPX1 in patients with the oculoauriculo-vertebral 

spectrum (OAVS). 

Hum Mol Genet, 15:581-587. IF 8,6 

Lohmann DR, Hausler T, Horsthemke B, Zeschnigk M. (2005) Minimal region of deletion on 

chromosomal arm 3p25.1-p25.2 in uveal melanoma. 

Cancer Res. 65:10634 IF 8,5 

Ludwig M, Katalinic A, Groß S, Sutcliffe A, Varon R, Horsthemke B (2005) Increased prevalence of 

imprinting defects in patients with Angelman syndrome born to subfertile couples. 

J Med Genet, 42:289-291 IF 6.4 

Irlbacher, H., Franke, J., Manke, T., Vingron, M. and A. E. Ehrenhofer-Murray (2005) Control of 

replication initiation and heterochromatin formation in Saccharomyces cerevisiae by a regulator of 

meiotic gene expression. 

Genes Dev 19:1811-22. IF 16.4 

Schaper, S., Franke, J., Meijsing, S. H. and A. E. Ehrenhofer-Murray (2005) Nuclear import of the 

histone acetyltransferase complex SAS-I in Saccharomyces cerevisiae. 

J Cell Sci 118(Pt 7):1473-84. IF 6.9 

Geissenhöner, A., C. Weise and A. E. Ehrenhofer-Murray (2004) Regulation of ORC function by 

NatAdependent N_-acetylation in Saccharomyces cerevisiae. 

Mol Cell Biol 24(23):10300-10312. IF 7.8 

Gautschi, M., S. Just, A. Mun, S. Ross, P. Rücknagel, Y. Dubaquie, A. E. Ehrenhofer-Murray and 

S. Rospert (2003) The yeast N_-acetyltransferase NatA is quantitatively anchored to the ribosome 

and interacts with nascent polypeptides. 

Mol Cell Biol 23: 7403 - 7414. IF 7.8 

Kasulke, D., S. Seitz and A. E. Ehrenhofer-Murray (2002) A role for the Saccharomyces cerevisiae 

RENT complex protein Net1 in HMR silencing. 

Genetics 161: 1411 - 1423. IF 4.1 

Grünweller, A. and A. E. Ehrenhofer-Murray (2002) A novel yeast silencer: The 2 micron origin of 

Saccharomyces cerevisiae has HST3-, MIG1- and SIR-dependent silencing activity. 

Genetics 162: 59 - 71. IF 4.1 

Meijsing, S. H. and A. E. Ehrenhofer-Murray (2002) The silencing complex SAS-I links histone 

acetylation to the assembly of repressed chromatin by CAF-I and Asf1 in Saccharomyces 

cerevisiae. Genes Dev 15: 3169 - 3182. IF 16.4


Prof. Dr. rer. nat. Ralf Küppers 

Institute for Cell Biology (Tumor Research) 


Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RSK, Küppers R, Dalla-Favera 

R (2001) Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphoma. 

Nature, 412, 341- 346 IF 32.2 

Schwering I, Bräuninger A, Klein U, Jungnickel B, Tinguely M, Diehl V, Hansmann M-L, Dalla- 

Favera R, Rajewsky K, Küppers R (2003) Loss of the B lineage-specific gene expression program 

in Hodgkin and Reed/Sternberg cells of Hodgkin’s lymphoma. 

Blood, 101, 1505-1512 (IF: 9.8) IF 10.4 

Küppers R, Klein U, Schwering I, Distler V, Bräuninger A, Cattoretti G, Tu Y, Stolovitzky GA, 

Califano A, Hansmann M-L, Dalla-Favera R (2003) Identification of Hodgkin and Reed-Sternberg 

cell-specific genes by gene expression profiling. 

J. Clin. Invest., 111, 529-537 IF 15.0 

Kurth J, Hansmann M-L, Rajewsky K, Küppers R (2003) Epstein-Barr virus-infected B cells 

expanding in germinal centers of infectious mononucleosis patients do not participate in the 

germinal center reaction. 

Proc. Natl. Acad. Sci. USA, 100, 4730-4735 IF 10.5 

Küppers R (2003) B cells under influence: transformation of B cells by Epstein-Barr virus. 

Nature Rev. Immunol. 3, 801-812 IF 30.5 

Messer, R.J., Dittmer, U., Peterson, K.E. & Hasenkrug, K.J. (2004) Essential roles for 

virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. 

Proc. Nat. Acad. Sci. USA 101:12260- 12265. IF 10.4 

Dittmer, U., He, H., Messer R.J., Schimmer, S., Olbrich, A.R.M., Ohlen, C., Greenberg P.D., 

Stromnes I.M., Iwashiro M., Sakaguchi S., Evans L.H., Peterson K.E., Yang, G. & Hasenkrug K.J. 

(2004) Functional impairment of CD8+ T cells by regulatory T cells during persistent retroviral 

infection. 

Immunity 20:293- 303. IF 15.4 

Bechtel D, Kurth J, Unkel C, Küppers R (2005) Transformation of BCR-deficient germinal-center 

B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and 

posttransplantation lymphoma. 

Blood, 106, 4345-4350 IF 10.4 

Küppers R (2005) Mechanisms of B cell lymphoma pathogenesis. 

Nature Rev. Cancer, 5, 251-262 IF 31.7 

Kraft, A.R.M., Krux, F., Schimmer, S., Ohlen, C., Greenberg, P.D. & Dittmer, U. (2007) CpG 

oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection. 

Blood 109:2982-2984. IF 10.1 

Balkow, S., Krux, F., Loser, K., Becker, J.U., Grabbe, S. & Dittmer, U. (2007) Friend retrovirus 

infection of myeloid dendritic cells impairs maturation, prolongs contact to naïve T cells, and favors 

expansion of regulatory T cells. 

Blood 110:3949-3958. IF 10.1


Prof. Dr. Süleyman Ergün 

Department of Anatomy 

6. Publications 

Kilic N, Oliveira-Ferrer L, Vahid SN, Irmak I, Obst-Pernberg K, Wurmbach J-H, Loges S, Kilic E, 

Weil J, Lauke H, Tilki D, Singer BB, Ergün S Lymphatic reprogramming of microvascular 

endothelial cells by CEArelated Cell Adhesion Molecule-1 via interaction with VEGFR-3 and Prox1. 

Blood 110: 4223-4233 (2007) IF 10.4 

Tilki D, Kilic N, Sevinc S, Zywietz F, Stief CG, Ergün S. Zone-specific remodeling of tumor blood 

vessels affects tumor growth. 

Cancer 110:2347-62 (2007) IF 4.6 

Zengin E, Chalajour F, Gehling UM, Ito WD, Treede H, Lauke H, Weil J, Reichenspurner H, Kilic N, 

and Ergün S. Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. 

Development 133, 1543-1551, (2006). IF 7.8 

Tilki D, Irmak S, Oliveira-Ferrer L, Hauschild J, Miethe K, Atakaya H, Hammerer P, Friedrich MG, 

Schuch G, Galalae R, Stief CG, Kilic E, Huland H, and Ergün S. CEA-related cell adhesion 

molecule-1 is involved in angiogenic switch in prostate cancer. 

Oncogene 25: 4965-74 (2006). IF 6.6 

Irmak S, Tilki D, Heukeshoven J, Oliveira-Ferrer L, Friedrich M, Huland H, and Ergün S. 

Stage-dependent increase of orosomucoid and zinc-alpha(2)-glycoprotein in urinary bladder 

cancer. Proteomics. 5, 4296-4304 (2005) IF 5.7 

Schuch G, Oliveira-Ferrer L, Loges S, Laack E, Bokemeyer C, Hossfeld DK, Fiedler W, Ergün S. 

Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. 

Leukemia, 19: 1312-1317 (2005) IF 6.1 

Oliveira-Ferrer L, Tilki D, Ziegeler G, Hauschild J, Loges S, Irmak S, Huland H, Friedrich M, 

Ergün S. Dual Role of CEACAM1 in Angiogenesis and Invasion of Human Urinary Bladder. 

Cancer Res, 64: 8932-8938 (2004) IF 7.7 

Ergün S, Buschmann C, Lauke H, Chalajour F, Kilic N, Strätling WH, Schumann GG. 

Cell type-specific expression of LINE-1 ORF1 and ORF2 in human embryonic and adult tissues. 

J Biol Chem, 279: 27753- 27763 (2004). IF 5.8 

Kilic N, Ferrer-Oliveira L, Loges S, Chalajour F, Weil J, Fernando M, Ergün S. Pro-angiogenic 

signaling by endothelial presence of CEA-related cell adhesion molecule-1 (CEACAM1). 

J Biol Chem, 280: 2361-2369 (2005) IF 5.8 

Benndorf R, Boger RH, Ergün S, Steenpass A, Wieland T. Angiotensin II type 2 receptor inhibits 

VEGFinduced migration and tube formation of human endothelial cells. 

Circ. Res., 93: 438-447 (2003) IF 9.9

WTZ Cancer Center Director Univ. Prof. Dr. med. Angelika Eggert ...

Create successful ePaper yourself

Delete template?

Save as template?